Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.55 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10884135 | 0.87 | TAAR1 (0.47) | MTNR1AMTNR1BALOX5NPSR1TAAR1 | |
| SCHEMBL13632416 | 0.84 | MEN1 (0.55) | MTNR1AMTNR1BNPSR1HPGD | |
| SCHEMBL20072234 | 0.82 | MTNR1A (0.59) | MTNR1AMTNR1BALOX5TAAR1SIGMAR1 | |
| SCHEMBL16244485 | 0.81 | TAAR1 (0.56) | MTNR1AMTNR1BALOX5TAAR1CA12 | |
| SCHEMBL23841132 | 0.78 | ALOX5 (0.52) | MTNR1AMTNR1BALOX5TAAR1SIGMAR1 | |
| SCHEMBL23803511 | 0.78 | ALOX5 (0.52) | MTNR1AMTNR1BALOX5TAAR1SIGMAR1 | |
| SCHEMBL28324732 | 0.78 | LMNA (0.56) | MTNR1AMTNR1BALOX5TAAR1 | |
| SCHEMBL18089027 | 0.78 | MTNR1A (0.58) | MTNR1AMTNR1BHPGD | |
| SCHEMBL7185351 | 0.77 | MTNR1A (0.54) | MTNR1AMTNR1BALOX5TAAR1SIGMAR1 | |
| SCHEMBL7189818 | 0.77 | ALOX5 (0.61) | MTNR1AMTNR1BALOX5TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787767-B2 | Modulators of mas-related g-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| EP-4135691-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20210340106-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. | 2021-11-04 | — | — | US | disclosed |
| WO-2021211839-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787767-B2 | Modulators of mas-related g-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | MTNR1A 49/4885MTNR1B 43/4885ALOX5 3106/4885 |
| US-20210340106-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | MTNR1A 49/4885MTNR1B 43/4885ALOX5 3106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.